phenyl (1-phenyl-1H-imidazol-4-yl)carbamate | 268538-46-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: phenyl (1-phenyl-1H-imidazol-4-yl)carbamate
• 英文别名: phenyl N-(1-phenylimidazol-4-yl)carbamate
• CAS: 268538-46-1
• 化学式: C₁₆H₁₃N₃O₂
• 分子量: 279.298
• InChiKey: ZOOVUDYXPJKYST-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  21
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  56.2
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  phenyl (1-phenyl-1H-imidazol-4-yl)carbamate 、 螺[异苯并呋喃-1(3H),4’-哌啶]-3-酮 生成 C₂₂H₂₀N₄O₃
  参考文献：
  名称：

  Aryl urea derivatives of spiropiperidines as NPY Y5 receptor antagonists

  摘要：

  Continuing medicinal chemistry studies to identify spiropiperidine-derived NPY Y5 receptor antagonists are described. Aryl urea derivatives of a variety of spiropiperidines were tested for their NPY Y5 receptor binding affinities. Of the spiropiperidines so far examined, spiro[3-oxoisobenzofurane-1(3H),4 '-piperidine] was a useful scaffold for producing orally active NPY Y5 receptor antagonists. Oral administration of 5c significantly inhibited the Y5 agonist-induced food intake in rats with a minimum effective dose of 3 mg/kg. In addition, this compound was efficacious in decreasing body weight in diet-induced obese mice. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.05.013
• 作为产物：
  描述：

  氯甲酸苯酯 、 1 - 苯基- 1H -咪唑-4 - 胺 在 吡啶 作用下， 生成 phenyl (1-phenyl-1H-imidazol-4-yl)carbamate
  参考文献：
  名称：

  Aryl urea derivatives of spiropiperidines as NPY Y5 receptor antagonists

  摘要：

  Continuing medicinal chemistry studies to identify spiropiperidine-derived NPY Y5 receptor antagonists are described. Aryl urea derivatives of a variety of spiropiperidines were tested for their NPY Y5 receptor binding affinities. Of the spiropiperidines so far examined, spiro[3-oxoisobenzofurane-1(3H),4 '-piperidine] was a useful scaffold for producing orally active NPY Y5 receptor antagonists. Oral administration of 5c significantly inhibited the Y5 agonist-induced food intake in rats with a minimum effective dose of 3 mg/kg. In addition, this compound was efficacious in decreasing body weight in diet-induced obese mice. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.05.013

文献信息

• Novel orally active NPY Y5 receptor antagonists: Synthesis and structure–activity relationship of spiroindoline class compounds
  作者：Toshihiro Sakamoto、Minoru Moriya、Hiroyasu Tsuge、Toshiyuki Takahashi、Yuji Haga、Katsumasa Nonoshita、Osamu Okamoto、Hirobumi Takahashi、Aya Sakuraba、Tomoko Hirohashi、Takunobu Shibata、Tetsuya Kanno、Junko Ito、Hisashi Iwaasa、Akira Gomori、Akane Ishihara、Takahiro Fukuroda、Akio Kanatani、Takehiro Fukami

  DOI：10.1016/j.bmc.2009.05.064

  日期：2009.7

  Spiroindoline urea derivatives, designed to act as NPY Y5 receptor antagonists, were synthesized and their structure–activity relationships were investigated. Of these derivatives, compound 3a showed good Y5 binding affinity with favorable pharmacokinetic properties. Compound 3a significantly inhibited bPP Y5 agonist-induced food intake in rats, and suppressed body weight gain in DIO mice.

  合成了设计用作NPY Y5受体拮抗剂的螺吲哚啉脲衍生物，并研究了它们的结构-活性关系。在这些衍生物中，化合物3a显示出良好的Y5结合亲和力和良好的药代动力学性质。化合物3a显着抑制了bPP Y5激动剂诱导的大鼠食物摄取，并抑制了DIO小鼠的体重增加。
• [EN] SPIRO-INDOLINES AS Y5 RECEPTOR ANTAGONISTS<br/>[FR] SPIRO-INDOLINES EN TANT QU'ANTAGONISTES DU RECEPTEUR Y5
  申请人：MERCK & CO INC

  公开号：WO2000027845A1

  公开（公告）日：2000-05-18

  Compounds of general structural formula (I) such as that shown in structural formula (II) are selective NPY Y5 receptor antagonists, useful in the treatment of obesity and the complications associated therewith.

  通用结构式（I）的化合物，例如结构式（II）所示的化合物，是选择性NPY Y5受体拮抗剂，可用于治疗肥胖及其相关并发症。
• Spiro-indolines as Y5 receptor antagonists
  申请人：Merck & Co., Inc.

  公开号：US20040063942A1

  公开（公告）日：2004-04-01

  Compounds of general structural formula I such as that shown in structural formula II 1 are selective NPY Y5 receptor antagonists, useful in the treatment of obesity and the complications associated therewith.

  通用结构式I所示的化合物，如结构式II1所示，是选择性的NPY Y5受体拮抗剂，可用于治疗肥胖及其相关并发症。
• SPIRO-INDOLINES AS Y5 RECEPTOR ANTAGONISTS
  申请人：Merck & Co., Inc.

  公开号：EP1129089A1

  公开（公告）日：2001-09-05
• EP1129089A4
  申请人：——

  公开号：EP1129089A4

  公开（公告）日：2003-01-22